StreetAlpha.app
Home › Stocks › SLS

SELLAS Life Sciences Group, Inc. (SLS)

Healthcare
$13.66
▼ −8.08%
LAST CLOSE · NOV 20

SELLAS develops cancer immunotherapy and targeted drug candidates for blood cancers and solid tumors. It last closed at $13.66 on Nov 20, down 8.08% on the day. The next earnings report for SLS is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, SLS reported EPS of -$0.05 on revenue of $0. Over its last 8 reports the stock moved an average of 7.5% the session after earnings. Over the last 12 months SLS insiders bought $0 of stock on the open market and sold $717K, according to SEC Form 4 filings.

AI Auto Pilots
Is SLS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SLS.

Key Stats

Last 12 months
Results
Net income
−$35.8M
EPS (diluted)
−$0.20
Valuation
Market cap
$2.8B
203.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$134.7M
At Sep 30
Shareholder equity
$131.8M
Shares outstanding
203.9M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $7.6M$7.6MFY2021FY2022: $1.0M$1.0MFY2022FY2023: $0$0FY2023

From SLS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · After the close
Reported EPS
-$0.05
Quarter ended Sep 2026
Year ago EPS
-$0.06
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.08Dec '24Mar 2025: -$0.07Mar '25Jun 2025: -$0.07Jun '25Sep 2025: -$0.06Sep '25Dec 2025: -$0.05Dec '25Mar 2026: -$0.05Mar '26Jun 2026: -$0.05Jun '26Sep 2026: -$0.05Sep '26Latest -$0.05
Revenue by quarter
Sep 2025: $0Sep '25Sep 2026: $0Sep '26Latest $0
How SLS moved after its last 8 reports
Average move the session after a report ±7.5%
Nov 12, 2026After the close−2.1%
Jul 27, 2026After the close−6.9%
May 12, 2026After the close+25.1%
Mar 19, 2026After the close−8.5%
Jan 8, 2026Time not announced−4.5%
Nov 12, 2025After the close−2.0%
Aug 12, 2025After the close−3.7%
May 13, 2025After the close+7.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SLSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Technical Analysis

SLS · as of the Nov 20 close · updated each morning
Uptrend

The stock is 23% above its 20 day and 18% above its 50 day average. It is 34% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot S1 at $12.97, and the nearest resistance the swing high (Jul 15) at $13.73.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 17.3%/day
Key levels
$24.8952 week high+82.2%
$14.77Pivot R1+8.1%
$14.08Pivot+3.1%
$13.73Swing high (Jul 15)+0.5%
$13.66Last close
$12.97Pivot S1−5.1%
$12.64Swing low (Sep 1)−7.5%
$11.95100 day average−12.5%
$11.1650 day average−18.3%
$10.5520 day average−22.8%
$9.05200 day average−33.7%
$1.3952 week low−89.8%
Indicators
RSI (14)56.48Middle of its rangeNeutral
MACD0.87Above its signal lineBullish
Stochastic47.0Middle of its rangeNeutral
ADX (14)33.3Trending up
Williams %R-63.3Oversold below −80, overbought above −20Neutral
CCI (20)81.3Oversold below −100, overbought above 100Neutral
Rate of change+62.2%Change over 10 sessionsBullish
ATR (14)$2.36Typical daily range, 17.3% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SLS

What happened before

See how SLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SLS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SLSHow many large options trades hit SLS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SLS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲141 buying vs 61 selling
  • ▼Held by funds -1.0 pts
  • ▲Funds holding +25
  • ▼Superinvestors: 0 added, 1 cut
  • ▲Put/call 4.45 to 1.67
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding219194+12.9%
In funds' top 1002−100.0%
Held by funds35.4%36.4%−1.0 pts
New / increased47 / 9459 / 78+2.9%
Reduced / sold out38 / 2326 / 28+13.0%
Put/call ratio1.674.45−62.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SLS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SLS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$717K3 sales · 3 insiders
2026-11 sold $717KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Angelos M. StergiouPresident and CEOSale26,606$19.18$510K
Nov 18Dragan CicicSVP, Chief Development OfficerSale6,933$19.18$133K
Nov 18John Thomas BurnsCFOSale3,831$19.18$73K
Nov 19, 2025Katherine Bach KalinDirectorBuy63,400$1.59$101K
Jun 12, 2025Nostrand Robert L VanDirectorBuy10,000$1.48$15K
May 30, 2025Jane WasmanDirectorBuy20,000$1.69$34K
Every insider buy and sale for SLS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SLS insider trades →

From SEC Form 4 filings by SLS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLS is in one of them and how their past SLS trades turned out.

SLS in the AI portfolios
Loading…

SLS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SLS in an article yet. Here's the latest on the wider market.

SLS in the news

About SELLAS Life Sciences Group

SELLAS is a clinical stage biopharmaceutical company based in New York that develops treatments for cancer. Its lead candidate, galinpepimut-S, is an immunotherapy that targets the WT1 protein, which is found in many types of cancer, including blood cancers such as acute myeloid leukemia. The company is also developing tambiciclib, a small molecule drug that inhibits CDK9, for patients with blood and solid cancers. Both candidates are in clinical trials.

Headquarters
New York, NY
Founded
2006